top button
    Got Questions


Global IoT Summit 2018
Oct 31, 2018
The Leela Palace, Bangalore



    Connect to us
      Facebook Login
      Site Registration Why to Join

Facebook Login
Site Registration

Pediatric Respiratory Disease Treatment Market : Lucrative Opportunities

0 votes
7 views

Pediatric Respiratory Disease Treatment Market: Introduction

  • Rise in global pollution levels have caused the pediatric population to be highly susceptible to a number of respiratory ailments. Pediatric respiratory disorders and symptoms include aerodigestive disorders (recurrent aspiration), asthma, chronic cough, and congenital abnormalities of airway & lung development including tracheobronchomalacia, cystic fibrosis, bronchopulmonary dysplasia (chronic lung disease), primary ciliary dyskinesia, recurrent respiratory infections & pneumonia, respiratory failure & ventilator dependency, sleep-apnea, and wheezing.

Report Overview @ https://www.transparencymarketresearch.com/pediatric-respiratory-disease-treatment-market.html

Key Drivers and Restraints of Global Pediatric Respiratory Disease Treatment Market

  • Rise in prevalence of respiratory disorders, changing lifestyle habits, progressive increase in obese pediatric population, and surge in awareness about pediatric care are anticipated to increase expenditure on pediatric respiratory disease treatment
  • Allergic rhinitis is the most common form of non-infectious rhinitis. According to the International Study on Asthma and Allergies in Childhood (ISAAC), prevalence of rhinitis varies between 0.8% and 14.9% in six to seven-year old children and between 1.4% and 39.7% in 13 to 14-year old children. Countries with a very low prevalence include Indonesia, Albania, Romania, Georgia, and Greece. Countries with a very high prevalence include Australia, New Zealand, and the U.K.
  • Government and non-government organizations focus on campaigns to increase awareness about pediatric health. Several associations and foundations are playing an active role in spreading awareness about various pediatric conditions such as short bowel syndrome, neuroblastoma, leukemia, cancer palliative care, respiratory diseases care, mental health, and neonatal care.
  • The American Academy of Pediatrics (AAP), Substance Abuse and Mental Health Services Administration (SAMHSA), the Child Health and Development Institute (CHDI), the World Child Cancer, the Indian Cancer Society, and others are engaged in creating awareness among people about pediatric disorders

Get a Glimpse of the In-Depth Analysis through our Comprehensive “Pediatric Respiratory Disease Treatment Market” Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75423

Asthma Segment to Lead Global Market

  • The global pediatric respiratory disease treatment market can be segmented based on drug class, disease type, distribution channel, and region
  • In terms of drug class, the global pediatric respiratory disease treatment market can be divided into anti-inflammatory drugs, bronchodilators, combination drugs, corticosteroid, monoclonal antibodies, and others. The combination drugs segment is expected to witness significant growth during the forecast period due to proven efficacy of these drugs in maintaining these conditions and promising pipeline of upcoming drugs in the segment.
  • Based on disease type, the global pediatric respiratory disease treatment market can be classified into asthma, cystic fibrosis, bronchiolitis, pneumonia, idiopathic pulmonary fibrosis, tuberculosis, and others. According to recent global statistics by the Global Asthma Network, nearly 334 million people across the world are affected by asthma. Among them, 14% are children and 8.6% are young adults (aged between 18 and 45 years). Prevalence is higher in developed countries than developing ones.
  • In terms of distribution channel, the global pediatric respiratory disease treatment market can be classified into hospitals & clinics, retail pharmacies, and online pharmacies

Asia Pacific to Offer Lucrative Opportunities in Global Pediatric Respiratory Disease Treatment Market

  • The global pediatric respiratory disease treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is a significant market for pediatric respiratory disease treatment due to strong emphasis on health care development and high health care expenditure.
  • Asia Pacific is also anticipated to offer lucrative opportunities in the pediatric respiratory disease treatment market. This can be attributed to high patient population, rise in awareness about pediatric care, and increase in focus of public & private organizations in preventing respiratory disorders in the developing countries.

Pre Book “Pediatric Respiratory Disease Treatment Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=75423&ltype=S

Key Players Operating in Global Pediatric Respiratory Disease Treatment Market

Leading players in the global pediatric respiratory disease treatment market are:

  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Merck & Co, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals
posted Feb 7 by Bella Watson

  Promote This Article
Facebook Share Button Twitter Share Button Google+ Share Button LinkedIn Share Button Multiple Social Share Button

Related Articles
0 votes

The global chronic kidney disease (CKD) drugs is predicted in a report by Transparency Market Research (TMR) finds intense competition and high fragmentation owing to presence of strong players in the market. Teva Pharmaceutical Industries Ltd., AstraZeneca Plc, Amgen Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, Kissei Pharmaceutical Co. Ltd., and Keryx Biopharmaceuticals Inc. are some of the leading makers of drugs for the treatment of chronic kidney diseases across the world.

The global chronic kidney disease drugs market registered at US$11.5 bn in 2015. Growing at a CAGR of 3.60% between 2016 and 2024, the market is expected to attain value of US$15.8 bn by the end of 2024. Calcium channel blockers surfaced as the key drug class in 2015, leading the market with a share of 18.9%.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2481

The hospitals segment, which is the current market leader, is expected to continue its dominance in this market over the next few years. North America led this market in 2015 with a share of 31.8%. This growth is driven by the strong economic condition of the region and the high acceptance for advanced technology products.

Increasing Incidence of Chronic Kidney Disease Mainly in Old People to Drive Growth

The global chronic kidney disease drugs market is primarily driven by the increasing incidence of chronic kidney disease among patients globally. This is boosted the need for the novel treatments to improve quality life of patients. Additionally, increasing geriatric population, who are more susceptible to adopt various diseases owing to their poor immunity, such as diabetes, cardiovascular disorders, and neurological conditions. Rising need for the drugs to treat this patients is boosting adoption of chronic kidney disease drugs. This is another important factor supporting growth of chronic kidney disease drugs market.

Additionally, the chronic kidney disease drugs market is projected to be propelled substantially in the near future owing to high technological advancements which are leading to the development of a numerous drugs, which will enable clinicians to provide proper assistance to chronic kidney disease patients.

Buy Now Chronic Kidney Disease Treatment Market Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=2481&ltype=S

Nonspecific Medication Buyers to Hamper Growth

However, developments and mechanical progresses in chronic kidney disease drugs are authorizing clinicians to offer genuine help to the patients, are expected to support growth of the market astoundingly. Additionally, the expanding inclination for nonspecific medication among buyers coupled with strengthening rivalry from biosimilars because of patent expiry is expected to limit the development of chronic kidney disease drugs market.

More Trending Reports by Transparency Market Research –

Erectile Dysfunction Drugs Market: prnewswire.com/news-releases/erectile-dysfunction-drugs-market-is-expected-to-reach-usd-34-billion-globally-in-2019-transparency-market-research-228593931.html

Veterinary Drugs Market: prnewswire.com/news-releases/veterinary-drugs-market-to-reach-us267-bn-by-2024-rising-inclination-toward-ensuring-health-and-wellness-of-companion-animals-to-aid-growth-says-tmr-615866193.html

0 votes

Transparency Market Research (TMR) has published a new report on the IBD (ulcerative colitis and Crohn’s disease) treatment market for the forecast period of 2019–2027. According to the report, the global IBD (ulcerative colitis and Crohn’s disease) treatment market was valued at ~US$ 15.5 Bn in 2018 and is projected to expand at a ~6% CAGR during the forecast period.

Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market: Overview

Inflammatory bowel disease is a group of medical conditions that causes chronic inflammation in the digestive tract. Inflammatory bowel disease is an umbrella term that comprises two principal disorders: ulcerative colitis and Crohn’s disease. Ulcerative colitis is a long-term medical indication that causes inflammation and sores in the inner lining of the colon and rectum.

Crohn’s disease is part of inflammatory bowel disease that causes inflammation to any part of the gastrointestinal tract, right from mouth to small intestine and anus. The exact cause of inflammatory bowel disease is not known; however, autoimmune disorders, genetic factors, and lifestyle changes are thought to cause the symptoms of inflammatory bowel disease in an individual. The common symptoms of inflammatory bowel disease include diarrhea, abdominal pain & cramps, constipation, rectal bleeding, weight loss, and fever.

Request PDF Sample of IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1473

Inflammatory bowel disease (IBD) affects men and women equally, and is more commonly observed in developed countries in the West than developing and underdeveloped countries. There is no permanent cure for this disease, and it requires lifetime treatment and management. However, the most preferred treatment option includes administration of medications such as aminosalicyclates, corticosteroids, biologic drugs, and integrin antagonists. In severe conditions, surgical treatments are also recommended.

Growth of the global IBD (ulcerative colitis and Crohn’s disease) treatment market can be attributed to rise in the prevalence of inflammatory bowel diseases across the world, development of novel drugs, novel pipeline drugs, and increase in access to the treatment of IBD. The availability and launch of biosimilar drugs for the treatment of IBD and rise in the adoption of biologic drugs are the other factors fueling the growth of the global IBD (ulcerative colitis and Crohn’s disease) treatment market. Rise in investments in building a robust pipeline for IBD and increase in lifestyle-related risk factors are likely to boost the growth of the global IBD treatment market.

North America dominated the global IBD (ulcerative colitis and Crohn’s disease) treatment market in 2018, and the trend is anticipated to continue during the forecast period. This can be ascribed to the presence of key players, increase in incidence of IBD, favorable reimbursement policies, and availability of novel drugs for IBD. However, the adverse side effects associated with IBD drugs and high cost of treatment are likely to restrain the global IBD treatment market during the forecast period.

New Product Development & Approvals to Drive Global Market

Inflammatory bowel diseases are characterized by chronic inflammation in the gastrointestinal tract, and primarily include Crohn’s disease and ulcerative colitis disease. The exact cause of inflammatory bowel disease is not known, and the high prevalence of these diseases has been witnessed in developed countries. Several medications such as corticosteroids, aminosalicylates, integrin antagonists, biologic drugs such as Tumor Necrosis Factor (TNF) inhibitors, and up to a certain extent, antibiotic drugs, are prescribed to provide relief from the symptoms of these diseases.

Buy Now “IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1473&ltype=S

The high prevalence and increase in incidence of Crohn’s disease and ulcerative colitis disease in developed countries has led to the development of novel therapeutics drugs. Biopharmaceutical companies have made significant investments in R&D, and numerous pipeline products are in various stages of clinical approvals, and likely to be commercialized during the forecast period.

AstraZeneca and Allergan are together developing the MEDI2070 interleukin-23 monoclonal antibody against ulcerative colitis and Crohn’s disease. MEDI2070 is currently in phase IIb of clinical trial for moderate to severe Crohn’s disease, and in phase II for ulcerative colitis. Pfizer’s PF-00547659 and Celgene’s Ozanimod are in phase II and phase III clinical trials, for Crohn’s Disease and ulcerative colitis, respectively. Additionally, the recent launch and approval of new drugs in North America, Europe, and Japan are projected to fuel the demand for IBD treatment drugs in the near future.

Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market: Prominent Regions

In terms of region, the global IBD (ulcerative colitis and Crohn’s disease) treatment market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global IBD (ulcerative colitis and Crohn’s disease) treatment market in 2018, followed by Europe.

North America accounted for a major share of the global market in 2018. This can be attributed to new product development, especially biologic drugs and approvals, well-established healthcare facilities, highest prevalence and incidence rates of IBD, and presence of key players in the region. Moreover, new pipeline products, increased clinical R&D budgets by both, government as well as private players, and rise in lifestyle-related risk factors are likely to fuel the demand for IBD treatments during the forecast period.

The market in Asia Pacific is projected to expand at the highest CAGR during the forecast period, owing to the large number of patients suffering from IBD disease in India, China, Australia, and New Zealand, rise in per capita medical expenditure, and increase in access to healthcare. The IBD (ulcerative colitis and Crohn’s disease) treatment markets in Latin America and the Middle East & Africa are likely to grow at a moderate pace during the forecast period.

Innovative Product Launches and Mergers & Acquisitions by Key Players to Drive Market

The global IBD (ulcerative colitis and Crohn’s disease) treatment market is consolidated in terms of number of players. A small number of players account for a majority share of the global market. Key players operating in the global IBD treatment market include Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB, Inc., and Biogen, Inc. These players have adopted various strategies such as product portfolio expansion, investment in research & development, development of novel IBD (ulcerative colitis and Crohn’s disease) treatment, and mergers & acquisitions to establish a strong distribution network.

For instance, in February 2018Janssen Biotech, Inc. and Theravance Biopharma, Inc. entered into a worldwide collaboration to develop TD-1473 for the treatment of inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease. In April 2019, Salix Pharmaceuticals entered into an exclusive license agreement with Mitsubishi Tanabe Pharma to commercialize and develop late stage investigational S1P modulators for the treatment of inflammatory bowel disease.

More Trending Reports by Transparency Market Research –

Non-invasive Prenatal Testing Market: prnewswire.com/news-releases/non-invasive-prenatal-testing-market-to-cross-us-5-000-million-by-2027—says-tmr-300865294.html

Global Wound Healing Market: prnewswire.com/news-releases/global-wound-healing-market-to-reach-over-us-350-billion-by-2025-says-tmr-676809663.html

0 votes

Chagas disease also known as American trypanosomiasis, was discovered by the Brazilian physician Carlos Chagas, in 1909. The Trypanosoma Cruzi parasite transmits the infectious disease to humans and animals. The disease is spread by insect vectors known as Triatominae or kissing bugs. Neglected parasitic infection (NPI) is a group of five parasitic diseases. Chagas disease in one of the NPI in the United States, targeted by the Centers for Disease Control and Prevention for community health action.

Report Overview @ https://www.transparencymarketresearch.com/chagas-disease-treatment-market.html

According to the World Health Organization’s report 2017, about six to seven million people are infected with Chagas disease, mostly in Latin America. Trypanosoma Cruzi parasites are mainly spread by urine/feces of infected blood sucking triatominae bugs. Triatominae bugs, carrying these parasites, live in the roof or wall cracks of houses. These insects hide during the day and are active at night, biting any uncovered areas of the skin.

Parasites from these bugs enter the human body when the individual unconsciously smears the bug’s excreta into the eyes, mouth, or inflamed skin. The disease also spreads through blood transfusion from an infected blood donor, laboratory accidents, organ transplanted from an infected donor, and by consuming foods contaminated with Trypanosoma Cruzi. An infected mother can pass the disease on to her child at the time of pregnancy or childbirth.

Chagas disease shows symptoms in two phases. The first or acute phase of symptoms lasts nearly two months after the infection. In this acute phase, large number of parasites circulates in systemic circulation. Symptoms in this stage are either mild, absent, or non-specific. In around 50% of people bitten by the triatominae bug, first visible indication is a purplish inflammation of an eyelid or skin lesion.

Request PDF Sample of Chagas Disease Treatment Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30458

Moreover, other indications include enlarged lymph glands, fever, muscle pain, swelling, headache, pallor, difficulty in breathing, and chest or abdominal pain. The second phase is the chronic phase. Parasites hide in the digestive muscles and heart. Nearly 10% of the patients suffer from neurological, digestive (usually enlargement of colon or esophagus), or mixed modifications. If neglected, it can lead to sudden death caused by progressive heart failure or cardiac arrhythmias owing to the damage caused to the cardiac muscles and the nervous system.

Chagas disease is detected by observing the parasite in blood smear by microscopic examination. Diagnosis can be made by two different serological tests. Lacks of nutrition (micronutrient and protein-energy malnutrition) exert a direct effect on the Chagas disease infection cause by Trypanosoma Cruzi, and rising the growth of Chagas disease treatment market. Lack of awareness about need for treatment of the disease and limited availability of treatment and medication can restrain the market growth.

Pre Book “Chagas Disease Treatment Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=30458&ltype=S

Chagas disease treatment market is segmented into three major categories: based on treatment, end-user, and region. In terms of treatment, the market is divided into two categories, medication and other possible treatments. Based on end-user, the market is bifurcated into hospital and clinical laboratories. Geographically, the global Chagas disease treatment market is divided into four broad regions: North America, Latin America, Asia Pacific, and Rest of the World. Latin America market is expected to grow significantly due to high prevalence rate of the disease, and increasing awareness about disease.

Key players operating in the global Chagas disease treatment market are Johnson & Johnson, KaloBios Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., ELEA SACIF Laboratory, and Bayer AG.

More Trending Reports by Transparency Market Research –

Shock Wave Therapy Device Market: prnewswire.com/news-releases/shock-wave-therapy-device-market-to-reach-us-1399-mn-by-2025-orthopedic-and-urology-application-leads-the-market-677627753.html

Life Sciences BPO Market: prnewswire.com/news-releases/life-sciences-bpo-market-is-expected-to-touch-us286-3-billion-by-2023—says-tmr-300813081.html

0 votes

Congenital Heart Disease Treatment Market: Introduction

  • Congenital heart disease is a structural heart issue existing at the time of birth. It is one of the most common types of birth defects across the globe.
  • In congenital heart disease, structure of the heart is developed abnormally. This includes defective heart valves, weak heart valves, and poor thickness of the heart arteries and veins. The abnormal heart structure leads to several complications such as low blood flow through the heart, blood flow in a wrong direction, and blockage of blood flow.

Report Overview @ https://www.transparencymarketresearch.com/congenital-heart-disease-treatment-market.html

  • Congenital heart disease can be diagnosed through physical examination and special heart tests. It can also be diagnosed during pregnancy.
  • Common symptoms of congenital heart disease include poor blood circulation, rapid breathing, cyanosis, and fatigue. Most patients with the congenital heart disease show very less or no symptoms at early stages of the disease.
  • The treatment of congenital heart disease includes use of drugs, catheter procedure, surgery, and heart transplant.

Global Congenital Heart Disease Treatment Market: Key Drivers

  • The global congenital heart disease treatment market is primarily driven by rise in the rate of incidence of congenital heart disease and launch of new products across the globe. The Centers for Disease Control and Prevention (CDC) estimates that one million children and one million adults in the U.S. are living with congenital heart disease currently.
  • Also, advancements in early diagnosis of congenital heart disease and availability of new therapeutic drugs are likely to fuel the global congenital heart disease treatment market during the forecast period
  • The family history of congenital heart disease and presence of underlying medical conditions, such as rubella, Type-1 diabetes, and Type-2 diabetes, during pregnancy increase chances of developing congenital heart disease in babies.

Get a Glimpse of the In-Depth Analysis through our Comprehensive “Congenital Heart Disease Treatment Market” Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75169

ACE Inhibitors Segment to Dominate Global Market

  • Based on drug class, the global congenital heart disease treatment market can be divided into angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers, antiarrhythmics, anticoagulants, antiplatelets, beta blockers, bosentan, digoxin, diuretics, sildenafil, and warfarin. The ACE inhibitors segment is anticipated to dominate the global market during the forecast period.
  • ACE inhibitors are most commonly used for the treatment of high blood pressure and congestive heart failure. The most commonly prescribed ACE inhibitors are captopril, enalapril, lisinopril, ramipril, and trandolapril.

Retail Pharmacy Segment to Dominate Global Market

  • In terms of distribution channel, the global congenital heart disease treatment market can be segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment is projected to dominate the global congenital heart disease treatment market during the forecast period.
  • Easy availability of drugs for the treatment of congenital heart disease at retail pharmacy stores, presence of a large number of retail pharmacy stores across the globe, and rapidly growing number of retail pharmacy chains are factors responsible for the leading share of the retail pharmacy segment.

Congenital Heart Disease Treatment Market in Asia Pacific to Expand Rapidly

  • In terms of region, the global congenital heart disease treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global market during the forecast period. However, the region is anticipated to lose market share by 2027.
  • High prevalence of congenital heart disease among people in the U.S., technological advancements in early diagnosis of the disease, and increase in awareness about congenital heart disease in the region are projected to drive the market in North America from 2019 to 2027
  • The congenital heart disease treatment market in Asia Pacific is projected to expand at a high CAGR during the forecast period, owing to rapid increase in the number of patients with congenital heart disease, high prevalence of diabetes in densely populated countries such as India, China, and South Korea, and rapidly improving health care infrastructure in the region.

Pre Book “Congenital Heart Disease Treatment Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=75169&ltype=S

Key Players Operating in Global Market

The global congenital heart disease treatment market is highly fragmented, with a large number of global players accounting for a major share of the market in respective regions. Key players operating in the global congenital heart disease treatment market are:

  • Novartis AG
  • Bayer AG
  • Merck & Co. Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Abbott
  • Orion Corporation
  • Cardiorentis Ag

More Trending Reports by Transparency Market Research –

Helicobacter Pylori (H. Pylori) Non-invasive Testing Market: prnewswire.com/news-releases/helicobacter-pylori-h-pylori-non-invasive-testing-market-to-be-worth-us-700-mn-by-2026-says-tmr-685104651.html

Brain Computer Interface Market: prnewswire.com/news-releases/brain-computer-interface-market-to-be-worth-us-12-billion-by-2024-demand-increases-with-growing-prevalence-of-brain-disorders—tmr-682767451.html

0 votes

Chronic Obstructive Pulmonary Disease Treatment Market: Introduction

Transparency Market Research has published a new report on the chronic obstructive pulmonary disease (COPD) treatment market. According to the report, the global chronic obstructive pulmonary disease treatment market was valued at ~US$ 17.4 Mn in 2018. The COPD treatment market is expected to expand at a CAGR of ~5% during the forecast period of 2019 to 2027.

Chronic obstructive pulmonary disease is a group of conditions affecting the lungs, which leads to difficulty in breathing. Chronic bronchitis and emphysema are two major indications included under chronic obstructive pulmonary disease (COPD). Breathlessness is a major characteristic of COPD. In case of emphysema, the alveoli (tiny air sacs) in the lungs are damaged. The walls of the alveoli are stretched, making the lungs bigger, resulting in difficulty in the movement of air. In chronic bronchitis, the bronchial airways (breathing tubes) inside the lungs are inflamed.

In terms of drug class, the combination therapy segment of the chronic obstructive pulmonary disease treatment market held a major share of the global COPD treatment market in 2018. It is likely to maintain its dominance in the chronic obstructive pulmonary disease treatment market during the forecast period, owing to its increased efficacy for COPD treatment.

Request PDF Sample of Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=73763

Based on distribution channel, the retail pharmacies segment of the COPD treatment market is estimated to account for a major share of the market. This segment of the chronic obstructive pulmonary disease treatment market is anticipated to expand at a rapid pace during the forecast period, owing to an increase in the number of COPD therapeutics being dispensed through retail pharmacies, and rise in the number of retail pharmacies in developing countries. Chronic obstructive pulmonary disease is characterized by progressive airflow limitation not fully reversible, and is a major cause of morbidity and mortality, worldwide. However, patent expiry of branded products and availability of generic equivalents and alternative treatment options are factors that are expected to hamper the growth of the global COPD treatment market during the forecast period.

Global Chronic Obstructive Pulmonary Disease Treatment Market: Prominent Regions

North America held a major share of the global chronic obstructive pulmonary disease treatment market. The COPD treatment market in the region is primarily driven by factors such as highly structured healthcare industry and availability of well-defined reimbursement policies from private and public health insurance firms. In addition, extensive research and development to provide advanced and efficient products, and a large number of players in the region, are factors driving the chronic obstructive pulmonary disease treatment market in North America.

The chronic obstructive pulmonary disease market in Asia Pacific is estimated to witness significant growth. Asia Pacific is a relatively untapped COPD treatment market as compared to developed regions. Hence, the region offers immense growth opportunities to market players. Factors such as high prevalence of chronic obstructive pulmonary disease, rise in geriatric population, surge in patient population, and growth of the healthcare industry are fueling the expansion of the COPD treatment market in the region.

Enquiry for Discount on “Chronic Obstructive Pulmonary Disease (COPD) Treatment Market” Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=73763

Europe held the second-largest share of the global chronic obstructive pulmonary disease treatment market in 2018. Well-developed healthcare infrastructure and increase in the number of incidences of chronic obstructive pulmonary disease are driving the COPD treatment market in the region. The chronic obstructive pulmonary disease treatment markets in the Middle East & Africa and Latin America are projected to witness moderate growth in the near future.

Chronic Obstructive Pulmonary Disease Treatment Market: Key Players

Key players are expanding their footprint to strengthen their position in the global chronic obstructive pulmonary disease treatment market. Emerging economies, due to increase in the number of patient population, and rise in tobacco smoking and air population, offer lucrative opportunities to key players to increase their market share. Manufacturers are engaging in new product development, collaborations, acquisitions, and distribution agreements. For instance, in July 2018, Orion Corporation signed a multi-year licensing agreement with Menarini to distribute and commercialize the former’s Easyhaler products. According to the agreement, Menarini would be supplying Orion’s products in Asia Pacific countries such as China, the Philippines, Malaysia, Hong Kong, Indonesia, Vietnam, Thailand, Singapore, South Korea, and Taiwan.

Prominent players operating in the global chronic obstructive pulmonary disease treatment market are AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.), CHIESI Farmaceutici S.p.A., Orion Corporation, and Mylan N.V.

...